Cerence Inc. (CRNC) Balance Sheet
As of 2026-06-30 (10-Q), Cerence Inc. (CRNC) reported total assets of $620.9M, total liabilities of $454.6M and shareholders' equity of $166.4M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $127.6M. Long-term debt: $173.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRNCCerence Inc.Follow CRNC — free
—
Price chart with a free account
- Market cap
- 377.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
| Line | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.14 | 0.13 | 0.09 | 0.10 | 0.12 | 0.08 | 0.13 | |
| Short-term investments | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | |
| Receivables | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.05 | |
| Inventory | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current assets | 0.25 | 0.29 | 0.23 | 0.23 | 0.27 | 0.19 | 0.21 | |
| Total assets | 1.69 | 1.71 | 1.32 | 1.30 | 0.70 | 0.63 | 0.62 | |
| Current liabilities | 0.20 | 0.17 | 0.15 | 0.15 | 0.22 | 0.10 | 0.10 | |
| Long-term debt | 0.27 | 0.27 | 0.26 | 0.28 | 0.19 | 0.20 | 0.17 | |
| Short-term debt | 0.01 | 0.01 | 0.01 | — | 0.09 | 0.00 | 0.00 | |
| Total liabilities | 0.73 | 0.67 | 0.61 | 0.60 | 0.56 | 0.48 | 0.45 | |
| Shareholders' equity | 0.96 | 1.03 | 0.71 | 0.69 | 0.14 | 0.15 | 0.17 |
USD billions · SEC XBRL
Cerence Inc. — questions
- How much cash does Cerence Inc. have?
- $127.6M in cash and cash equivalents as of 2026-06-30.
- How much debt does Cerence Inc. have?
- $173.5M of long-term debt and $0 due within a year as of 2026-06-30.
- What are Cerence Inc.'s total assets?
- $620.9M as of 2026-06-30.
- What is Cerence Inc.'s shareholders' equity?
- $166.4M as of 2026-06-30.
Every figure on this page comes from Cerence Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.